FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170888880> ?p ?o ?g. }

• W2170888880 abstract "Rationale Phase I/II studies of autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) were initiated, based on results of experimental transplantation in animal models of multiple sclerosis and clinical observations in patients treated concomitantly for malignant disease. Patients Eighty-five patients with progressive MS were treated with autologous HSCT in 20 centers and reported to the autoimmune disease working party of the European Group for Blood and Marrow Transplantation (EBMT). 52 (61 %) were female, median age was 39 [20-58] years. The median interval from diagnosis to transplant was 7 [1-26] years. Patients suffered from severe disease with a median EDSS score of 6.5 [4.5-8.5]. Active disease prior to transplant was documented in 79 of 82 evaluable cases. Results The stem cell source was bone marrow in 6 and peripheral blood in 79, and stem cells were mobilized into peripheral blood using either cyclophosphamide combined with growth factors or growth factors alone. Three patients experienced transient neurological complications during the mobilization phase. The high dose regimen included combination chemotherapy, with or without anti-lymphocyte antibodies or, with or without, total body irradiation. The stem cell transplants were purged of lymphocytes in 52 patients. Median follow-up was 16 [3-59] months. There were 7 deaths, 5 due to toxicity and infectious complications, 2 with neurological deterioration. The risk of death of any cause at 3 years was 10 (±7)% (95 % confidence interval). Neurological deterioration during transplant was observed in 22 patients; this was transient in most but was associated with MS progression in 6 patients. Neurological improvement by ≥ 1 point in the EDSS score was seen in 18 (21 %) patients. Confirmed progression-free survival was 74 (±12)% at 3 years being 66 (±23)% in patients with primary progressive MS but higher in patients with secondary progressive or relapsing-remitting MS, 78 (±13)%; p = 0.59. The probability of confirmed disease progression was 20 (±11)%. MRI data were available in 78 patients before transplant showing disease activity (gadolinium enhancing, new or enlarging lesions) in 33 %. Posttransplant MRI showed activity at any time in 5/61 (8 %) evaluable cases. Conclusion Autologous HSCT suggest positive early results in the management of progressive MS and is feasible. These multicentre data suggest an association with significant mortality risks especially in some patient groups and are being utilised in the planning of future trials to reduce transplant related mortality." @default.
• W2170888880 created "2016-06-24" @default.
• W2170888880 creator A5000549712 @default.
• W2170888880 creator A5003790920 @default.
• W2170888880 creator A5004647173 @default.
• W2170888880 creator A5005528907 @default.
• W2170888880 creator A5006337596 @default.
• W2170888880 creator A5013393489 @default.
• W2170888880 creator A5015657745 @default.
• W2170888880 creator A5015669455 @default.
• W2170888880 creator A5016850985 @default.
• W2170888880 creator A5023798810 @default.
• W2170888880 creator A5034008882 @default.
• W2170888880 creator A5038633707 @default.
• W2170888880 creator A5042354936 @default.
• W2170888880 creator A5046994122 @default.
• W2170888880 creator A5052064208 @default.
• W2170888880 creator A5054950406 @default.
• W2170888880 creator A5059915616 @default.
• W2170888880 creator A5066894053 @default.
• W2170888880 creator A5067116063 @default.
• W2170888880 creator A5067994259 @default.
• W2170888880 creator A5072385860 @default.
• W2170888880 creator A5074509169 @default.
• W2170888880 creator A5080898581 @default.
• W2170888880 creator A5084457753 @default.
• W2170888880 date "2005-06-01" @default.
• W2170888880 modified "2023-10-18" @default.
• W2170888880 title "Hematopoietic Stem Cell Transplantation for Multiple Sclerosis" @default.
• W2170888880 cites W100830138 @default.
• W2170888880 cites W1890599385 @default.
• W2170888880 cites W1939687029 @default.
• W2170888880 cites W1977031650 @default.
• W2170888880 cites W1978703555 @default.
• W2170888880 cites W2007107405 @default.
• W2170888880 cites W2011044675 @default.
• W2170888880 cites W2016090826 @default.
• W2170888880 cites W2034382093 @default.
• W2170888880 cites W2044664793 @default.
• W2170888880 cites W2058360786 @default.
• W2170888880 cites W2074051982 @default.
• W2170888880 cites W2090173240 @default.
• W2170888880 cites W2098137179 @default.
• W2170888880 cites W2106528383 @default.
• W2170888880 cites W2112142021 @default.
• W2170888880 cites W2125701590 @default.
• W2170888880 cites W2146183778 @default.
• W2170888880 cites W2151997047 @default.
• W2170888880 cites W2396355640 @default.
• W2170888880 cites W2402149436 @default.
• W2170888880 cites W2413562337 @default.
• W2170888880 cites W2443930017 @default.
• W2170888880 doi "https://doi.org/10.1001/archneur.62.6.860" @default.
• W2170888880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15956156" @default.
• W2170888880 hasPublicationYear "2005" @default.
• W2170888880 type Work @default.
• W2170888880 sameAs 2170888880 @default.
• W2170888880 citedByCount "55" @default.
• W2170888880 countsByYear W21708888802012 @default.
• W2170888880 countsByYear W21708888802013 @default.
• W2170888880 countsByYear W21708888802014 @default.
• W2170888880 countsByYear W21708888802015 @default.
• W2170888880 countsByYear W21708888802016 @default.
• W2170888880 countsByYear W21708888802017 @default.
• W2170888880 countsByYear W21708888802020 @default.
• W2170888880 countsByYear W21708888802021 @default.
• W2170888880 countsByYear W21708888802022 @default.
• W2170888880 crossrefType "journal-article" @default.
• W2170888880 hasAuthorship W2170888880A5000549712 @default.
• W2170888880 hasAuthorship W2170888880A5003790920 @default.
• W2170888880 hasAuthorship W2170888880A5004647173 @default.
• W2170888880 hasAuthorship W2170888880A5005528907 @default.
• W2170888880 hasAuthorship W2170888880A5006337596 @default.
• W2170888880 hasAuthorship W2170888880A5013393489 @default.
• W2170888880 hasAuthorship W2170888880A5015657745 @default.
• W2170888880 hasAuthorship W2170888880A5015669455 @default.
• W2170888880 hasAuthorship W2170888880A5016850985 @default.
• W2170888880 hasAuthorship W2170888880A5023798810 @default.
• W2170888880 hasAuthorship W2170888880A5034008882 @default.
• W2170888880 hasAuthorship W2170888880A5038633707 @default.
• W2170888880 hasAuthorship W2170888880A5042354936 @default.
• W2170888880 hasAuthorship W2170888880A5046994122 @default.
• W2170888880 hasAuthorship W2170888880A5052064208 @default.
• W2170888880 hasAuthorship W2170888880A5054950406 @default.
• W2170888880 hasAuthorship W2170888880A5059915616 @default.
• W2170888880 hasAuthorship W2170888880A5066894053 @default.
• W2170888880 hasAuthorship W2170888880A5067116063 @default.
• W2170888880 hasAuthorship W2170888880A5067994259 @default.
• W2170888880 hasAuthorship W2170888880A5072385860 @default.
• W2170888880 hasAuthorship W2170888880A5074509169 @default.
• W2170888880 hasAuthorship W2170888880A5080898581 @default.
• W2170888880 hasAuthorship W2170888880A5084457753 @default.
• W2170888880 hasBestOaLocation W21708888801 @default.
• W2170888880 hasConcept C126322002 @default.
• W2170888880 hasConcept C203014093 @default.
• W2170888880 hasConcept C2777408962 @default.
• W2170888880 hasConcept C2780640218 @default.
• W2170888880 hasConcept C28328180 @default.
• W2170888880 hasConcept C2911091166 @default.
• W2170888880 hasConcept C71924100 @default.

• next